Oya Natsuo, Sasai Keisuke, Tachiiri Seiji, Sakamoto Takashi, Nagata Yasushi, Okada Takashi, Yano Shinsuke, Ishikawa Takayuki, Uchiyama Takashi, Hiraoka Masahiro
Department of Therapeutic Radiology and Oncology, Graduate School of Medical Sciences, Kyoto University, Kyoto, Japan.
Int J Hematol. 2006 Jan;83(1):86-91. doi: 10.1532/IJH97.05046.
This study evaluated patients for the influence of the dose rate and lung dose of fractionated total body irradiation (TBI) in preparation for allogeneic bone marrow transplantation (BMT) on the subsequent development of interstitial pneumonitis (IP). Sixty-six patients at our institute were treated with TBI followed by BMT. All of the patients received a total TBI dose of 12 Gy given in 6 fractions over 3 days and were divided into 3 groups according to the radiation dose rate and lung dose: group A, lung dose of 8 Gy (n = 18); group B, lung dose of 12 Gy at 8 cGy/min (n = 25); and group C, lung dose of 12 Gy at 19 cGy/min (n = 23). The overall survival rate, the cumulative incidence of relapse, and the cumulative incidence of IP were evaluated in relation to various potential indicators of future IP. There were no significant differences in survival and relapse rates between patient group A and combined groups B and C. Clinically significant IP occurred in 13 patients. The cumulative incidence of IP was significantly higher in patients who developed acute parotitis as indicated by either an elevation in the serum amylase level or parotid pain of grade 1 to 2. There was no difference in IP incidence among groups A, B, and C. There was no significant difference in IP incidence between lung dose values of 8 Gy (with lung shielding) and 12 Gy (without lung shielding) and between dose rate values of 8 cGy/min and 19 cGy/ min, at least when TBI was given in 6 fractions. The presence of acute parotitis during or just after TBI may be a predictor of IP.
本研究评估了在异基因骨髓移植(BMT)准备过程中,分次全身照射(TBI)的剂量率和肺部剂量对随后发生间质性肺炎(IP)的影响。我院66例患者接受了TBI治疗,随后进行BMT。所有患者均接受了总量为12 Gy的TBI,分6次在3天内给予,并根据辐射剂量率和肺部剂量分为3组:A组,肺部剂量8 Gy(n = 18);B组,肺部剂量12 Gy,剂量率8 cGy/min(n = 25);C组,肺部剂量12 Gy,剂量率19 cGy/min(n = 23)。根据未来IP的各种潜在指标,评估了总生存率、复发累积发生率和IP累积发生率。A组患者与B组和C组合并组之间的生存率和复发率无显著差异。13例患者发生了具有临床意义的IP。血清淀粉酶水平升高或1至2级腮腺疼痛所表明发生急性腮腺炎的患者中,IP累积发生率显著更高。A、B、C组之间的IP发生率无差异。至少当TBI分6次给予时,8 Gy(有肺部屏蔽)和12 Gy(无肺部屏蔽)的肺部剂量值之间以及8 cGy/min和19 cGy/min的剂量率值之间的IP发生率无显著差异。TBI期间或刚结束后出现急性腮腺炎可能是IP的一个预测指标。